Opaleye Management Inc. bought $80k of ETON
owner at Eton Pharmaceuticals, Inc.. 10,000 shares at an average of $7.98, traded Oct 23, 2024, filed Oct 25, 2024.
Score components
- +12Role10% owner
- +9Trade size$80k at market
- -5Relative to holdingsUnder 1% of holdings (0.4%)
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +38.5%, 3m +105.5%, 6m +95.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-24-042516, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 23, 2024 | POpen-market purchase Common Stock, par value $0.001 per shareindirect: By Opaleye, L.P. | +10,000 | $7.98 | $80k | 2,770,000 | Oct 25, 2024 |
Related signals
Other insiders at Eton Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | ETONsell Eton Pharmaceuticals, Inc. | David Krempa Chief Business Officer | $229k 4,166 shares | -9% | |
| 47Moderate | ETONsell Eton Pharmaceuticals, Inc. | James R. Gruber Chief Financial Officer | $674k 41,713 shares | -17% | |
| 41Moderate | Eton Pharmaceuticals, Inc. | David Krempa Chief Business Officer | $504k 34,000 shares | -5% | |
| 27Weak | ETONbuy Eton Pharmaceuticals, Inc. | Opaleye Management Inc. owner | $125k 7,930 shares | +0% | |
| 58Moderate | Eton Pharmaceuticals, Inc. | Sean Brynjelsen President & CEO | $3.6M 210,000 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.